Zacks Research Has Optimistic Outlook of TEVA Q1 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities research analysts at Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a report issued on Tuesday, December 3rd. Zacks Research analyst R. Department now anticipates that the company will earn $0.49 per share for the quarter, up from their previous forecast of $0.48. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.36 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q3 2026 earnings at $0.81 EPS.

TEVA has been the subject of a number of other reports. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, Barclays boosted their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Down 2.7 %

Shares of NYSE TEVA opened at $17.33 on Friday. The company has a market cap of $19.63 billion, a price-to-earnings ratio of -20.39, a PEG ratio of 1.06 and a beta of 0.79. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries has a 12 month low of $9.35 and a 12 month high of $19.31. The stock has a 50-day moving average price of $17.54 and a two-hundred day moving average price of $17.38.

Insider Buying and Selling

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.55% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of the company. Sanctuary Advisors LLC boosted its position in Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after acquiring an additional 664 shares during the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 0.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after purchasing an additional 805 shares in the last quarter. Smithfield Trust Co grew its stake in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares during the period. Signaturefd LLC increased its holdings in Teva Pharmaceutical Industries by 16.9% in the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after purchasing an additional 1,094 shares in the last quarter. Finally, Bridgewater Associates LP increased its holdings in Teva Pharmaceutical Industries by 5.2% in the third quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock worth $418,000 after purchasing an additional 1,144 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.